Literature DB >> 28133789

Diagnostic performance of procalcitonin, presepsin, and C-reactive protein in patients with hematological malignancies.

Yasuhiro Ebihara1, Kiyoko Kobayashi1, Akaru Ishida2, Tomoya Maeda3, Naoki Takahashi3, Yoshitada Taji4, Norio Asou3, Kenji Ikebuchi1,2.   

Abstract

INTRODUCTION: Infections represent a major complication of hematological malignancies. C-reactive protein (CRP) and procalcitonin (PCT) have been used as diagnostic biomarkers of infections, but do not produce definitive findings. Recently, a new biomarker, presepsin, has been used as a diagnostic tool for detecting infections in the fields of emergency and neonatal medicine. However, the usefulness of presepsin for identifying infections in patients with hematological malignancies, including those who develop febrile neutropenia, remains unclear.
METHODS: In this study, we retrospectively analyzed the utility of PCT, presepsin, and CRP as biomarkers of infections during 49 febrile episodes that occurred in 28 patients with hematological malignancies.
RESULTS: The levels of PCT, but not those of CRP or presepsin, were significantly higher in the infection group than in the uninfected group (P<.03), indicating that PCT might be a more sensitive biomarker of infections. No differences in presepsin levels were detected between the patients with and without neutropenia, or between the infected and uninfected patients with neutropenia, indicating that presepsin might have less diagnostic value in patients with neutropenia.
CONCLUSIONS: We conclude that PCT might provide additional information and could be used in combination with other biomarkers to detect infections in patients with hematological malignancies.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  C-reactive protein; hematological malignancy; neutropenia; presepsin; procalcitonin

Mesh:

Substances:

Year:  2017        PMID: 28133789      PMCID: PMC6817173          DOI: 10.1002/jcla.22147

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  21 in total

Review 1.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors.

Authors:  K L Becker; E S Nylén; J C White; B Müller; R H Snider
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

2.  Management of fever of unknown origin in the neutropenic patient: the Japanese experience.

Authors:  T Masaoka
Journal:  Int J Hematol       Date:  1998-10       Impact factor: 2.490

Review 3.  The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever.

Authors:  M Limper; M D de Kruif; A J Duits; D P M Brandjes; E C M van Gorp
Journal:  J Infect       Date:  2010-03-27       Impact factor: 6.072

4.  The clinical role of procalcitonin in hematopoietic SCT.

Authors:  J Koya; Y Nannya; M Ichikawa; M Kurokawa
Journal:  Bone Marrow Transplant       Date:  2012-02-20       Impact factor: 5.483

5.  Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values?

Authors:  Camille Chenevier-Gobeaux; Eloise Trabattoni; Marie Roelens; Didier Borderie; Yann-Erick Claessens
Journal:  Clin Chim Acta       Date:  2013-09-27       Impact factor: 3.786

6.  Phagocytosis by human monocytes is required for the secretion of presepsin.

Authors:  Yasuyuki Arai; Kiyomi Mizugishi; Kazuhiko Nonomura; Katsuki Naitoh; Akifumi Takaori-Kondo; Kouhei Yamashita
Journal:  J Infect Chemother       Date:  2015-05-06       Impact factor: 2.211

7.  Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG).

Authors:  C Viscoli
Journal:  Eur J Cancer       Date:  2002-03       Impact factor: 9.162

Review 8.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

9.  The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia.

Authors:  Vincas Urbonas; Audronė Eidukaitė; Indrė Tamulienė
Journal:  Cytokine       Date:  2013-03-17       Impact factor: 3.861

10.  Clinical impact of kidney function on presepsin levels.

Authors:  Takanobu Nagata; Yoshinari Yasuda; Masahiko Ando; Tomoko Abe; Takayuki Katsuno; Sawako Kato; Naotake Tsuboi; Seiichi Matsuo; Shoichi Maruyama
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

View more
  7 in total

1.  Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies.

Authors:  Ahmad Baraka; Marwa Zakaria
Journal:  Int J Hematol       Date:  2018-04-03       Impact factor: 2.490

2.  Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study.

Authors:  Lucie Probst; Enrico Schalk; Tobias Liebregts; Vanja Zeremski; Asterios Tzalavras; Michael von Bergwelt-Baildon; Nina Hesse; Johanna Prinz; Jörg Janne Vehreschild; Alexander Shimabukuro-Vornhagen; Dennis A Eichenauer; Jorge Garcia Borrega; Matthias Kochanek; Boris Böll
Journal:  J Intensive Care       Date:  2019-08-07

3.  Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma.

Authors:  Bettina M Knoll; Jibran Ahmed; Michael Karass; Amandeep Aujla; Patricia McHale; Patricia Kretschmer; Amitabha Mazumder; Karen Seiter; Tauseef Ahmed; Seah H Lim
Journal:  Am J Hematol       Date:  2018-12-31       Impact factor: 10.047

4.  Association of Procalcitonin with the Patient's Infection Characteristics and Prognosis after Hematopoietic Stem Cell Transplantation.

Authors:  Shan-Shan Li; Jun-Xu Gu; Xiao-Wei Li; Na Zhang; Mei Jia; Lin Pei; Ming Su
Journal:  Dis Markers       Date:  2022-09-13       Impact factor: 3.464

5.  Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients.

Authors:  Amanda G Blouin; Meier Hsu; Martin Fleisher; Lakshmi V Ramanathan; Stephen M Pastores
Journal:  Clin Chim Acta       Date:  2020-07-15       Impact factor: 3.786

6.  Procalcitonin for Diagnostics and Treatment Decisions in Pediatric Lower Respiratory Tract Infections.

Authors:  Philipp Baumann; Gurli Baer; Jessica Bonhoeffer; Aline Fuchs; Verena Gotta; Ulrich Heininger; Nicole Ritz; Gabor Szinnai; Jan Bonhoeffer
Journal:  Front Pediatr       Date:  2017-08-28       Impact factor: 3.418

7.  Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies.

Authors:  Mina Yang; Seung Jun Choi; Jaewoong Lee; Dong Gun Lee; Yoon-Joo Kim; Yeon-Joon Park; Eun-Jee Oh
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.